NCT07459283 2026-03-10
The Safety, Dosimetry and Efficacy of 177Lu-INN805 in Patients With Malignant Solid Tumors
FindCure Biosciences (ZhongShan) Co., Ltd.
Phase EARLY_PHASE1 Not yet recruiting
Clinical Trials
6 trialsNCT03215095 2025-07-17
RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT02145143 2025-06-18
Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Completed
NCT06898437 2025-04-15
Study of 177Lu-LNC1004 Injection in FAP-positive Radioiodine-refractory Differentiated Thyroid Cancer
Peking Union Medical College Hospital
Phase EARLY_PHASE1 Recruiting
NCT03574051 2018-07-16
the Microbiota Are Associated With Iodine-131 Therapy and Hypothyroidism
First Affiliated Hospital of Harbin Medical University
Phase EARLY_PHASE1 Unknown
NCT00718770 2014-01-17
A Pilot Clinical Trial for Poorly Differentiated Thyroid Cancer - Correlation to Retinoid and Peroxisome-proliferator-activated Receptor (PPARy) Expression
University of Colorado, Denver
Phase EARLY_PHASE1 Completed